SeaStar Medical Holding Corporation - Common Stock (ICU)
1.9050
-0.0050 (-0.26%)
SeaStar Medical Holding Corporation is a biotechnology company focused on developing innovative therapies to enhance the treatment of life-threatening kidney conditions
The company is primarily engaged in researching and creating advanced medical devices and technologies designed to improve the care of patients with acute kidney injury and other renal-related disorders. By leveraging its proprietary approach, SeaStar Medical aims to provide solutions that reduce the need for dialysis and improve patient outcomes, ultimately transforming the standard of care in nephrology.
Nuwellis shares are trading higher Monday after the company announced Friday that the first pediatric patient has been treated with the newly launched Quelimmune therapy in a commercial setting.
SeaStar announced that the FDA has agreed to the final labeling for QUELIMMUNE, a novel treatment for children with acute kidney injury and sepsis who require kidney replacement therapy.
Shares of Alcoa Corporation (NYSEAA) rose sharply in today’s pre-market trading after the company reported better-than-expected sales for its first quarter.
